Arrowhead Pharmaceuticals, Inc. (ARWR) is a Biotechnology company in the Healthcare sector, currently trading at $66.69. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ARWR = $2,295.71 (+3342.4% from the current price, the stock appears undervalued). Analyst consensus target is ARWR = $79 (+18.1% upside).
Valuation: ARWR trades at a trailing Price-to-Earnings (P/E) of 45.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.66.
Financials: revenue is $829M, +60%/yr average growth. Net income is $2M (loss), growing at -36.2%/yr. Net profit margin is -0.2% (negative). Gross margin is 97.1% (+1.4 pp trend).
Balance sheet: total debt is $366M against $466M equity (Debt-to-Equity (D/E) ratio 0.79, moderate). Current ratio is 4.86 (strong liquidity). Debt-to-assets is 26.4%. Total assets: $1.4B.
Analyst outlook: 14 / 20 analysts rate ARWR as buy (70%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 61/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 66/100 (Partial), Future 79/100 (Pass), Income 10/100 (Fail).
